Publication date: Jun 17, 2024
Giant congenital melanocytic nevi (GCMN) can be cosmetically significant and can lead to melanoma. There is no standard pharmacologic treatment for GCMN. We present the case of an 8-year-old female with kaposiform lymphangiomatosis caused by an NRAS mutation whose nevus spilus-type GCMN improved on oral selumetinib.
| Concepts | Keywords |
|---|---|
| Cosmetically | kaposiform lymphangiomatosis |
| Giant | MEK inhibitor |
| Lymphangiomatosis | nevus spilus |
| Mutation | NRAS |
| Pharmacologic |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | nevus |
| disease | MESH | melanocytic nevus |
| drug | DRUGBANK | Selumetinib |
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
Original Article
(Visited 3 times, 1 visits today)